CRL for Minerva’s Schizophrenia Drug Cites Multiple Clinical and Nonclinical Issues

February 28, 2024 |

Minerva Neurosciences has received a complete response letter (CRL) from the FDA on an NDA for the company’s schizophrenia drug roluperidone.
Source: Drug Industry Daily